ReviewArchives of pharmacal research2026
Targeting histamine signaling: repurposing antihistamines for cancer chemotherapy and immunotherapy.
Review in Archives of pharmacal research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Despite major advances in oncology, effective cancer treatment remains a major clinical challenge. Repurposing approved drugs offers a promising approach for developing novel therapies for various diseases, including cancer. Among key pathophysiological mediators, histamine and its receptors have emerged as important regulators of cancer cell growth, proliferation, metastasis, and drug resistance, presenting new opportunities for using antihistamines in cancer treatment. Histamine signals through four distinct types of receptors, H1R-H4R, each displaying mechanistic diversity; therefore, understanding the subtype-specific signaling of these receptors is important for interpreting their therapeutic relevance. This review examines the current evidence on how histamine and its receptors influence carcinogenesis, discussing the role of various histamine receptor antagonists in modulating oncogenic signaling pathways and the tumor microenvironment. This review highlights the potential role of antihistamines as adjuncts to existing cancer chemotherapies and immunotherapies.
Indexed as
Identifiers
42842089What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.